Medios AG Names Thomas Meier as New CEO in Leadership Transition

Medios AG, Germany's first listed specialty pharmaceutical company, has announced a significant leadership transition with the appointment of Thomas Meier as the new Chief Executive Officer effective February 1, 2026. Meier brings substantial international experience from his current role as CEO of Swiss CDMO company Bachem Holding AG, where he has demonstrated strong leadership since 2020. His background includes previous positions as Chief Operations Officer at Bachem and Head of Manufacturing at Peninsula Laboratories in California, positioning him as an ideal candidate to drive Medios Group's continued growth in the European Specialty Pharma market. The appointment represents a strategic move for Medios as it seeks to expand its pioneering work in individualized medicine across its operations in Germany, the Netherlands, Belgium, and Spain.

Dr. Yann Samson, Chairman of the Supervisory Board, expressed confidence in Meier's ability to deliver capital-efficient, profitable growth while acknowledging outgoing CEO Matthias Gaertner's decade of outstanding service. Gaertner, who will remain in office until December 31, 2025, was credited with having a decisive influence on Medios' growth and success during his tenure. Meier himself emphasized his commitment to continuing the company's successful strategy and strengthening Medios' position in the European Specialty Pharma sector. The leadership change comes as Medios prepares for important financial milestones, including the Quarterly Statement as of September 30, 2025, and participation in key industry conferences such as the mwb inspired Conference in Hamburg and Berenberg European Conference in the UK.

As a leading provider of Specialty Pharma solutions, Medios supports partners throughout the supply chain with innovative services focused on making cutting-edge therapies accessible through pharmacies, specialist practices, and pharmaceutical companies. The company's shares trade on the Frankfurt Stock Exchange's Prime Standard and are included in the SDAX selection index, reflecting its established market position. Readers can find additional information about Medios' approach to individualized medicine through their official website at www.medios.group, which provides comprehensive details about their mission to advance personalized healthcare solutions across Europe. The original announcement was distributed through NEWMEDIAWIRE, highlighting the significance of this executive transition for investors and industry stakeholders alike.